New Medical Treatment Strategies for Nonalcoholic Steatohepatitis-Reference-Cited by-同舟云学术

New Medical Treatment Strategies for Nonalcoholic Steatohepatitis

Published:2015-03-21 Issue:2 Volume:13 Page:259-273
ISSN:1092-8472
Container-title:Current Treatment Options in Gastroenterology
language:en
Short-container-title:Curr Treat Options Gastro

Author:

Fuchs Michael

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s11938-015-0053-z.pdf

Reference97 articles.

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.

2. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11(1):1–16.

3. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339–50.

4. Sanyal AJ. NASH: a global health problem. Hepatol Res. 2011;41(7):670–4.

5. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593–608.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease;Journal of Gastroenterology and Hepatology;2021-06-23

2. Emerging Circulating Biomarkers for The Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis;Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease;2019